Definium Therapeutics (DFTX) Stock Jumps 20% After LSD-Based Drug Hits Phase 3 Goal

TLDR

• Definium Therapeutics (DFTX) stock jumped nearly 20% after its Phase 3 Panorama study of DT120 ODT met its primary endpoint in generalized anxiety disorder.
• Patients on DT120 ODT 100µg saw HAM-A scores drop 9.8 points vs. 4.7 points for placebo at Week 12.
• This is the third positive Phase 3 study for DT120 ODT overall, following two earlier trials in anxiety and depression.
• Discontinuation rates were nearly identical between drug and placebo groups (10.4% vs. 10.3%), suggesting good tolerability.
• Definium plans to file an NDA with the FDA in the first half of 2027, with a pre-NDA meeting scheduled for Q4 2026.

Definium Therapeutics (DFTX) stock surged nearly 20% in premarket trading on Monday after the company announced positive topline results from its Phase 3 Panorama study, its LSD-based treatment DT120 ODT for generalized anxiety disorder (GAD).

The stock has now nearly tripled in value this year, driven by growing regulatory and investor interest in psychedelic-based therapies.

… Continue reading the full article at the original source below.